Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Metrics to compare | MAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMAPPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | 23.2x | −0.6x | |
PEG Ratio | −0.11 | −0.04 | 0.00 | |
Price/Book | 1.6x | 2.3x | 2.6x | |
Price / LTM Sales | 3.3x | 1.8x | 3.3x | |
Upside (Analyst Target) | 90.0% | 15.6% | 38.7% | |
Fair Value Upside | Unlock | 5.1% | 5.1% | Unlock |